NIVEGU.KNOW BEFORE YOU FLY

THE WORLD OF AVIATION.
YOUR JOURNEY, EXPLAINED.

NASDAQ / LIVE COMPANY INTELLIGENCE

AC Immune SA

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERACIU
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / ACIU COVERAGE

What’s moving AC Immune SA now

Current reporting with the operating signal separated from the noise.

01
AC Immune SA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026

AC Immune SA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026

Investors are testing whether AC Immune SA’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
02
AC Immune SA ACIU

AC Immune SA ACIU

The story matters when it changes AC Immune SA’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
AC Immune says early data from anti-inflammatory drug gives wider clinical momentum for pipeline

AC Immune says early data from anti-inflammatory drug gives wider clinical momentum for pipeline

The story matters when it changes AC Immune SA’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
AC IMMUNE SA Earnings Results: $ACIU Reports Quarterly Earnings

AC IMMUNE SA Earnings Results: $ACIU Reports Quarterly Earnings

Investors are testing whether AC Immune SA’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
05
AC Immune SA Beat Analyst Profit Forecasts, And Analysts Have New Estimates

AC Immune SA Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Investors are testing whether AC Immune SA’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
06
AC Immune SA (NASDAQ:ACIU) stock most popular amongst individual investors who own 32%, while private equity firms hold 29%

AC Immune SA (NASDAQ:ACIU) stock most popular amongst individual investors who own 32%, while private equity firms hold 29%

Investors are testing whether AC Immune SA’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
PRIMARY DOCUMENTS / SEC EDGAR

Latest ACIU filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

6-KOfficial SEC filingFiled 2026-11-04 · Period 2026-11-03SEC ↗6-KOfficial SEC filingFiled 2026-10-02 · Period 2026-10-02SEC ↗3/AOfficial SEC filingFiled 2026-10-09 · Period 2026-10-02SEC ↗3Official SEC filingFiled 2026-10-09 · Period 2026-10-02SEC ↗6-KOfficial SEC filingFiled 2026-09-23 · Period 2026-09-23SEC ↗6-KOfficial SEC filingFiled 2026-09-03 · Period 2026-09-03SEC ↗6-KOfficial SEC filingFiled 2026-08-20 · Period 2026-08-20SEC ↗6-KOfficial SEC filingFiled 2026-08-11 · Period 2026-08-11SEC ↗
EARNINGS / QUARTERLY TRACKER

AC Immune SA, quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.